Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Clinical and Economic Outcome Analysis of First-Line Immunosuppression in Acquired Hemophilia a

Ellen Cusano, Julia Hews-Girard, Mujtaba Basharat, Lindsay Cowley, Julie Grabell, Nancy Hodgson, Kelly Pittman, Allison Rupnaraine, Rowan Thillaye-Kerr, Brendan Cord Lethebe, Paula James, Roy Khalife, Natasha Pardy, Chai W. Phua, Oksana C. Prokopchuk-Gauk, Michelle Sholzberg, Haowei Linda Sun, Man-Chiu Poon, M. Dawn Goodyear

Blood (2024) 144 (Supplement 1): 554.

https://doi.org/10.1182/blood-2024-202551

Published: 2024

Journal Articles

Low-Dose Immune Tolerance Induction Therapy for Severe Hemophilia a Inhibitor Patients: Immunosuppressants Improve Outcomes but Are Generally Not Necessary for Inhibitor-Titer below 200 BU/Ml

Zhengping Li, Man-Chiu Poon, Runhui Wu

Blood (2023) 142 (Supplement 1): 3988.

https://doi.org/10.1182/blood-2023-184514

Published: 2023

Journal Articles

Long-Term Eltrombopag in Children with Chronic Immune Thrombocytopenia: A Single-Center Extended Real-Life Observational Study in China

Zhifa Wang, Nan Wang, Juntao Ouyang, Jingyao Ma, Man-Chiu Poon, Zhenping Chen, Xiaoling Cheng, Runhui Wu

Blood (2023) 142 (Supplement 1): 2590.

https://doi.org/10.1182/blood-2023-185812

Published: 2023

Journal Articles

Experience with Emicizumab Among People with Hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry

Man-Chiu Poon, Adrienne Lee, Federico Germini, Arun Keepanasseril, Quazi Ibrahim, Letizia Polito, Katya Moreno, Michelle Santos, Emma Iserman, Davide Matino, Alfonso Iorio

Blood (2023) 142 (Supplement 1): 1240.

https://doi.org/10.1182/blood-2023-174057

Published: 2023

Journal Articles

Comparison of Activated Clotting Time to Hepcon Protamine Titration for Anticoagulation Management during Cardiopulmonary Bypass Surgery in a Patient with Severe Hemophilia a on Emicizumab Prophylaxis

Ellen Cusano, Haowei Linda Sun, M Dawn Goodyear, Man-Chiu Poon, Douglas Seal, R Scott McClure, Natalia Rydz

Blood (2022) 140 (Supplement 1): 2759–2761.

https://doi.org/10.1182/blood-2022-168133

Published: 2022

Journal Articles

Shorter Time Interval from Inhibitor Detection to Starting Low-Dose Immune Tolerance Induction Therapy Is Associated with Better Inhibitor Eradication Outcomes in Severe Hemophilia a Children with High-Titer Inhibitors in China

Zhengping Li, Man-Chiu Poon, Guoqing Liu, Zekun Li, Jie Sun, Runhui Wu

Blood (2022) 140 (Supplement 1): 2757–2758.

https://doi.org/10.1182/blood-2022-164999

Published: 2022

Journal Articles

Real-World Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry

Man-Chiu Poon, Adrienne Lee, Federico Germini, Arun Keepanasseril, Quazi Ibrahim, Francis Nissen, Katya Moreno, Michelle Santos, Emma Iserman, Davide Matino, Alfonso Iorio

Blood (2022) 140 (Supplement 1): 8465–8467.

https://doi.org/10.1182/blood-2022-157531

Published: 2022

Journal Articles

A Pharmacist-Managed Hydroxyurea Prescribing Protocol Improves Uptake and Optimization Among Patients with Sickle Cell Disease within the Southern Alberta Rare Blood and Bleeding Disorders (SARBBD) Comprehensive Care Program

Cameron Roessner, Trudy Sale, Man-Chiu Poon, Dawn Goodyear, Adrienne Lee, Natalia Rydz

Blood (2021) 138 (Supplement 1): 1896.

https://doi.org/10.1182/blood-2021-153914

Published: 2021

Journal Articles

Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

Man-Chiu Poon, Adrienne Lee, Federico Germini, Arun Keepanasseril, Quazi Ibrahim, Francis Nissen, Fabian Sanabria, Michelle Santos, Emma Iserman, Davide Matino, Alfonso Iorio

Blood (2021) 138 (Supplement 1): 347.

https://doi.org/10.1182/blood-2021-147195

Published: 2021

Journal Articles

Platelet Membrane Procoagulation in Preeclampsia

Adrienne Lee, MD, Lorriane Chow, BSc, MD FRCPC, Leslie Skeith, MD, Joshua A Nicholas, BHSc, MD, Man-Chiu Poon, MD, Alastair W. Poole, MA, PhD VetMB, Ejaife O Agbani, PhDBPharm,MSc

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-137213

Published: 2020

Journal Articles

Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

Adrienne Lee, MD, Federico Germini, MD MSc, Man-Chiu Poon, MD, Arun Keepanasseril, Quazi Ibrahim, MSc, Aijing Shang, MD PhD, Francis Nissen, Oliver Meier, Cami S. Sima, MD, Davide Matino, Alfonso Iorio, MDPhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137320

Published: 2020

Journal Articles

Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome

Matthew C. Sims, Louisa Mayer, Janine H. Collins, Tadbir K. Bariana, Karyn Megy, Cecile Lavenu-Bombled, Denis Seyres, Laxmikanth Kollipara, Frances S. Burden, Daniel Greene, Dave Lee, Antonio Rodriguez-Romera, Marie-Christine Alessi, William J. Astle, Wadie F. Bahou, Loredana Bury, Elizabeth Chalmers, Rachael Da Silva, Erica De Candia, Sri V. V. Deevi, Samantha Farrow, Keith Gomez, Luigi Grassi, Andreas Greinacher, Paolo Gresele, Dan Hart, Marie-Françoise Hurtaud, Anne M. Kelly, Ron Kerr, Sandra Le Quellec, Thierry Leblanc, Eva B. Leinøe, Rutendo Mapeta, Harriet McKinney, Alan D. Michelson, Sara Morais, Diane Nugent, Sofia Papadia, Soo J. Park, John Pasi, Gian Marco Podda, Man-Chiu Poon, Rachel Reed, Mallika Sekhar, Hanna Shalev, Suthesh Sivapalaratnam, Orna Steinberg-Shemer, Jonathan C. Stephens, Robert C. Tait, Ernest Turro, John K. M. Wu, Barbara Zieger, NIHR BioResource, Taco W. Kuijpers, Anthony D. Whetton, Albert Sickmann, Kathleen Freson, Kate Downes, Wendy N. Erber, Mattia Frontini, Paquita Nurden, Willem H. Ouwehand, Remi Favier, Jose A. Guerrero

Blood (2020) 136 (17): 1956–1967.

https://doi.org/10.1182/blood.2019004776

Published: 2020

Includes: Supplemental data

Journal Articles

Low-Dose Immune Tolerance Induction for Hemophilia a Children with Poor-Risk High-Titer Inhibitors

Zekun Li, MBBS, Zhenping Chen, PhDMD, Xiaoling Cheng, Xinyi Wu, Li Gang, Zhen Yingzi, Cai Siyu, Man-Chiu Poon, Runhui Wu, MD PhD

Blood (2019) 134 (Supplement_1): 1122.

https://doi.org/10.1182/blood-2019-132021

Published: 2019

Journal Articles

An Update on rFVIIa Use in Females with Rare Bleeding Disorders

Meera B. Chitlur, MD, Manuel Carcao, David Cooper, Shilpa Jain, Kaan Kavakli, Bryce Kerlin, Skye Peltier, Man-Chiu Poon, Hossam Saad, Amy Shapiro

Blood (2019) 134 (Supplement_1): 1119.

https://doi.org/10.1182/blood-2019-130298

Published: 2019

Journal Articles

Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada

Haowei Linda Sun, MD FRCPC, Ming Yang, PhD, Man-Chiu Poon, MD, Adrienne Lee, MD, Katherine Sue Robinson, MD, Michelle Sholzberg, MDM, MSc, FRCPC, John K. Wu, MBBS, FRCPC, MS, Alfonso Iorio, MD PhD, Victor S. Blanchette, FRCP, Robert J Klaassen, MD FRCPC, Shannon Jackson, MD FRCPC

Blood (2018) 132 (Supplement 1): 4813.

https://doi.org/10.1182/blood-2018-99-113858

Published: 2018

Journal Articles

Attitudes Toward Prenatal Diagnosis and Pregnancy Management in Carriers of Hemophilia: A Qualitative Analysis Exploring the Views of Carriers in Southern Alberta

Gwynivere A Davies, MDFRCPC, Man-Chiu Poon, MD, Natalia Rydz, MD, M. Dawn Goodyear, MD

Blood (2016) 128 (22): 4742.

https://doi.org/10.1182/blood.V128.22.4742.4742

Published: 2016

Journal Articles

Low Dose Secondary/Tertiary Prophylaxis Is Feasible and Effective in Resource Limited Setting in South India for Children with Hemophilia

Neeraj Sidharthan, MDDM, Vijayakumar Narayana Pillai, MBBS DCH, Sheena Mathew, MBBS DNB, Remya Sudevan, MBBS MPH, Dinkar Viswam, BPT, Cilla Joseph, MPT, Sumi Soman, MSc, Archana Vijay, MBBS MD, Adrienne Lee, MD, Man-Chiu Poon, MD

Blood (2016) 128 (22): 2336.

https://doi.org/10.1182/blood.V128.22.2336.2336

Published: 2016

Journal Articles

Characterization of aberrant splicing of von Willebrand factor in von Willebrand disease: an underrecognized mechanism

Lindsey Hawke, Mackenzie L. Bowman, Man-Chiu Poon, Mary-Frances Scully, Georges-Etienne Rivard, Paula D. James

Blood (2016) 128 (4): 584–593.

https://doi.org/10.1182/blood-2015-10-678052

Published: 2016

Includes: Supplemental data

Journal Articles

Premature changes in trabecular and cortical microarchitecture result in decreased bone strength in hemophilia

Adrienne Lee, Steven K. Boyd, Gregory Kline, Man-Chiu Poon

Blood (2015) 125 (13): 2160–2163.

https://doi.org/10.1182/blood-2014-10-602060

Published: 2015

Journal Articles

The Rate of Pregnancy Loss in Von Willebrand Disease: A Cross-Sectional Study

Leslie Skeith, MD, Natalia Rydz, MD, M. Dawn Goodyear, MD, Man-Chiu Poon, MD

Blood (2014) 124 (21): 2843.

https://doi.org/10.1182/blood.V124.21.2843.2843

Published: 2014

NARROW

Clinical and Economic Outcome Analysis of First-Line Immunosuppression in Acquired Hemophilia a

Low-Dose Immune Tolerance Induction Therapy for Severe Hemophilia a Inhibitor Patients: Immunosuppressants Improve Outcomes but Are Generally Not Necessary for Inhibitor-Titer below 200 BU/Ml

Long-Term Eltrombopag in Children with Chronic Immune Thrombocytopenia: A Single-Center Extended Real-Life Observational Study in China

Experience with Emicizumab Among People with Hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry

Comparison of Activated Clotting Time to Hepcon Protamine Titration for Anticoagulation Management during Cardiopulmonary Bypass Surgery in a Patient with Severe Hemophilia a on Emicizumab Prophylaxis

Shorter Time Interval from Inhibitor Detection to Starting Low-Dose Immune Tolerance Induction Therapy Is Associated with Better Inhibitor Eradication Outcomes in Severe Hemophilia a Children with High-Titer Inhibitors in China

Real-World Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry

A Pharmacist-Managed Hydroxyurea Prescribing Protocol Improves Uptake and Optimization Among Patients with Sickle Cell Disease within the Southern Alberta Rare Blood and Bleeding Disorders (SARBBD) Comprehensive Care Program

Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

Platelet Membrane Procoagulation in Preeclampsia

Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry

Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome

Low-Dose Immune Tolerance Induction for Hemophilia a Children with Poor-Risk High-Titer Inhibitors

An Update on rFVIIa Use in Females with Rare Bleeding Disorders

Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada

Attitudes Toward Prenatal Diagnosis and Pregnancy Management in Carriers of Hemophilia: A Qualitative Analysis Exploring the Views of Carriers in Southern Alberta

Low Dose Secondary/Tertiary Prophylaxis Is Feasible and Effective in Resource Limited Setting in South India for Children with Hemophilia

Characterization of aberrant splicing of von Willebrand factor in von Willebrand disease: an underrecognized mechanism

Premature changes in trabecular and cortical microarchitecture result in decreased bone strength in hemophilia

The Rate of Pregnancy Loss in Von Willebrand Disease: A Cross-Sectional Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only